DiaSorin is an Italian specialty IVD company with revenues of approximately $1.5 billion in 2025, specializing in immunoassay for specialty testing, molecular diagnostics, and clinical chemistry. DiaSorin is the global leader in vitamin D testing — a dominant market position in a high-volume specialty immunoassay segment — and holds strong positions in infectious disease serology, bone metabolism, and endocrinology testing. The company's 2021 acquisition of Luminex significantly expanded its molecular diagnostics portfolio, adding multiplex syndromic testing and flow cytometry-based immunoassay platforms. DiaSorin's LIAISON platform is deployed in immunoassay laboratories globally.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — Specialty Immunoassay Leadership, Luminex Integration, and Molecular Expansion Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — LIAISON Platform, Luminex xMAP, Specialty Immunoassay, and IP
• Latest Products and Services — New Specialty Assays, Luminex Integration, and Pipeline
• M&A — Luminex Integration Progress, Joint Ventures, and Partnerships 2023-2025
• Marketing Tactics — Specialty Testing Market Strategy and Channel Positioning
• Organization and Management — Leadership, Structure, and Workforce
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. DiaSorin — Key Financial Metrics Summary 2023-2025
Table 2. DiaSorin — Revenue by Segment 2023-2025
Table 3. DiaSorin — Revenue by Geography 2023-2025
Table 4. DiaSorin — R&D Investment 2023-2025
Table 5. DiaSorin — SWOT Analysis
Table 6. DiaSorin — Core Technology Capabilities and Key Platforms
Table 7. DiaSorin — Key Analyzers and Reagent Portfolio
Table 8. DiaSorin — M&A Activity Summary 2023-2025
Table 9. DiaSorin — Key Management and Leadership
Table 10. DiaSorin — Strategic Priorities 2025-2030
